All In Biotech

NDA 215211 · Amicus Therap US

Opfolda

Miglustat · Oral · Glucosylceramide Synthase Inhibitor; Enzyme Stabilizer

Breakthrough therapyOrphan

Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 28, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30

10 Phase 3, 2 recruiting

FAERS reports

264

186 serious, 30 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 27, 2024.

OPFOLDA is indicated, in combination with Pombiliti, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). OPFOLDA is an enzyme stabilizer indicated, in combination with Pombiliti, a hydrolytic lysosomal glycogen-specific enzyme, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). ( 1 )

Mechanism: Miglustat binds with, stabilizes, and reduces inactivation of cipaglucosidase alfa-atga in the blood after infusion. The bound miglustat is dissociated from cipaglucosidase alfa-atga after it is internalized and transported into lysosomes. Miglustat alone has no pharmacological activity in cleaving glycogen.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 28, 2023 Original approval · Type 5 - New Formulation or New Manufacturer Breakthrough therapyOrphanLabelLetterReview
1 products under this application
  • OPFOLDA · MIGLUSTAT 65MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Miglustat" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pneumonia24
  • seizure24
  • diarrhoea20
  • vomiting15
  • off label use14
  • nausea12
  • pyrexia12
  • asthenia11
  • condition aggravated11
  • fatigue11
  • respiratory failure11
  • weight decreased11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20101
20114
20123
20133
20171
201810
201912
202011
202116
202218
202321
202451
202564
202648

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Opfolda (Miglustat)

2024 spending

$41K

Beneficiaries

22

163 claims

Per beneficiary

$1,844

$33.47 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$40,568

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 43 on PubMed

Sponsor: Amicus Therap US

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.